View all trials
Are you a member? Sign in above to view additional information
  • Study title
    A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
  • Protocol ID
    LOXO-TRK-15003
  • Disease
    Disease Type Disease Subtype
  • Eligibility criteria
  • Study Status
    Open
  • Location(s)
    Sydney Children's Hospital
    • Centre Study Status:
      Open
    • Notes:
  • Phase
    Phase 1/2
  • Study type
    Treatment
  • Diagnosis stage
  • Study open date
    11/09/2017
  • Study close date
    N/A
  • Study chair
  • Sponsor
    Bayer
Back to search results